RNAZ (TransCode Therapeutics) Moat Score: 3/10 (As of Jun. 27, 2026)


RNAZ TransCode Therapeutics Inc RNAZ
32 GF Score
Price $4.84
! 1 Warning Sign
View Full Analysis

What is TransCode Therapeutics Moat Score?

TransCode Therapeutics RNAZ +10.69% 32 Moat Score is 3 as of Jun. 27, 2026. GuruFocus rates RNAZ with a GF Score™ of 32/100. The stock has 1 warning sign investors should review. Among 1,404 Biotechnology companies, TransCode Therapeutics ranks better than 75.5% on this metric.

TransCode Therapeutics has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

TransCode Therapeutics has No Moat: TransCode Therapeutics Inc has some intellectual property but operates in a highly competitive biotech sector with transient advantages. The company lacks strong brand loyalty, significant market share, or regulatory barriers that would provide a sustainable competitive advantage.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes TransCode Therapeutics might have No Moat - Very weak/transient advantages.

TransCode Therapeutics  (NAS:RNAZ) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

TransCode Therapeutics Moat Score Related Terms

RNAZ vs ARTL, GLMD, DCOY: Moat Score Comparison

For the Biotechnology subindustry, TransCode Therapeutics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TransCode Therapeutics Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TransCode Therapeutics's Moat Score distribution charts can be found below:

* The bar in red indicates where TransCode Therapeutics's Moat Score falls into.


RNAZ
32GF Score
TransCode Therapeutics Inc RNAZ
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
TransCode Therapeutics (RNAZ) has a Moat Score of 3 as of Jun. 27, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, TransCode Therapeutics ranks #344 out of 1404 companies in the Biotechnology industry, placing it in the top 24.5%.
Is TransCode Therapeutics' Moat Score too high?
TransCode Therapeutics' current Moat Score is 3. The Biotechnology industry median Moat Score is 2.00. TransCode Therapeutics' value of 3 is 50% above this industry median. Based on the distribution chart, TransCode Therapeutics ranks #344 out of 1404 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, TransCode Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does TransCode Therapeutics' Moat Score compare to ARTL and GLMD?
According to the Biotechnology industry distribution chart, TransCode Therapeutics ranks #344 out of 1404 companies for Moat Score. This places TransCode Therapeutics in the top 25% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. TransCode Therapeutics' value of 3 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,404 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TransCode Therapeutics's current Moat Score of 3 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TransCode Therapeutics's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TransCode Therapeutics stock overvalued right now?
TransCode Therapeutics (RNAZ) has a current Moat Score of 3. The current Moat Score is 3 and 50% above the Biotechnology industry median of 2.00. TransCode Therapeutics' overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For TransCode Therapeutics (RNAZ), the current Moat Score is 3 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

TransCode Therapeutics Business Description

Address 6 Liberty Square, No. 2382, Boston, MA, USA, 02109
TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.
32GF Score

Get the complete analysis for RNAZ

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.84
Price